|
|
|
| Application progress of hydrogels in image-guided radiotherapy for pro-state cancer |
| PANG Yongpeng TIAN Long ZHAO Xin |
| Department of Radiotherapy, the First Affiliated Hospital of Hebei Northern University, Hebei Province, Zhangjiakou 075000, China |
|
|
|
|
Abstract With the development of image-guided technology, the accuracy of prostate cancer target location has been significantly improved. Accurate target location is a prerequisite for increasing the output dose of prostate cancer and reducing the toxicity of dangerous organs. The toxicity of most of dangerous organs in image-guided radiotherapy (IGRT) for prostate cancer has been effectively controlled, but there is still a certain probability of radiation proctitis. Hydrogel is a kind of adjuvant radiotherapy instrument that can effectively reduce the rectal toxicity of prostate cancer IGRT. Currently, hydrogel is widely used in foreign countries, but it is rarely used in China. The main contents of domestic and foreign application reviews are focused on the protective effect of hydrogels on rectum. This review introduces the latest progress in the application of hydrogels in prostate cancer IGRT, including the surgical procedure of combined gold benchmark markers and the safety evaluation of hydrogel injection. At the same time, the effect of hydrogel on reducing rectal toxicity is further summarized. It is hoped that this review will provide some theoretical reference for the further application of hydrogels in China.
|
|
|
|
|
|
[1] Persson E，Emin S，Scherman J，et al. Investigation of the clinical inter-observer bias in prostate fiducial marker image registration between CT and MR images [J]. Radiat Oncol，2021，16（1）：150.
[2] Moll M，Wei?覻 M，Stanisav V，et al. Effects of gold fiducial marker implantation on tumor control and toxicity in external beam radiotherapy of prostate cancer [J]. Radiol Oncol，2023， 57（1）：95-102.
[3] Tanaka O，Maejima R，Yama E，et al. Radiotherapy for prostate cancer：Effect of gold fiducial markers on diffusion-weighted magnetic resonance imaging [J]. Asia Pac J Clin Oncol，2021，17（1）：79-83.
[4] M?覿kel?覿 P，Wright C，Anttinen M，et al. Safety and efficacy of MRI-guided transurethral ultrasound ablation for radiorecurrent prostate cancer in the presence of gold fiducial markers [J]. Acta Radiol，2023，64（3）：1228-1237.
[5] Lim Joon D，Berry C，Harris B，et al. A clinical study comparing polymer and gold fiducials for prostate cancer radiotherapy [J]. Front Oncol，2023，12：1023288.
[6] Gupta PK，Rastogi N，Maria Das KJ，et al. A dose escalated fiducial marker-based image guided radical radiotherapy in locally advanced prostate cancers：A single institute experience from India [J]. J Cancer Res Ther，2023，19（2）：382- 388.
[7] Reynaud T，Ben Aicha I，Carignan D，et al. Infection after prostatic transrectal fiducial marker implantation for image guided radiation therapy [J]. Cancer Radiother，2023，27（3）：214-218.
[8] Gómez-Aparicio MA，Valero J，Caballero B，et al. Extreme Hypofractionation with SBRT in Localized Prostate Cancer [J]. Curr Oncol，2021，28（4）：2933-2949.
[9] Rose C，Ebert MA，Mukwada G，et al. Intrafraction motion during CyberKnife■ prostate SBRT：impact of imaging frequency and patient factors [J]. Phys Eng Sci Med，2023，46 （2）：669-685.
[10] Lischalk JW，Blacksburg S，Mendez C，et al. Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease [J]. Radiat Oncol，2021，16（1）：126.
[11] Toriumi R，Yaegashi H，Sakurai T，et al. Ischemic proctitis after low-dose-rate brachytherapy using hydrogel spacer for prostate cancer [J]. IJU Case Rep，2022，5（4）：237-240.
[12] Nakamura Y，Soma T，Izumi K，et al. Screening of chronic radiation proctitis and colorectal cancer using periodic total colonoscopy after external beam radiation therapy for pros- tate cancer [J]. Jpn J Clin Oncol，2021，51（8）：1298-1302.
[13] Kesavan A，Vickneson K，Esuvaranathan K. Hospital readmissions for patients with prostate cancer are higher after radiotherapy than after prostatectomy [J]. Investig Clin Urol，2022，63（1）：34-41.
[14] Ferini G，Pergolizzi S. A Ten-year-long Update on Radiation Proctitis Among Prostate Cancer Patients Treated With Curative External Beam Radiotherapy [J]. In Vivo，2021，35（3）：1379-1391.
[15] Armstrong N，Bahl A，Pinkawa M，et al. SpaceOAR Hydrogel Spacer for Reducing Radiation Toxicity During Radiotherapy for Prostate Cancer. A Systematic Review [J]. Urology，2021，156：e74-e85.
[16] Repka MC，Creswell M，Lischalk JW，et al. Rationale for Utilization of Hydrogel Rectal Spacers in Dose Escalated SBRT for the Treatment of Unfavorable Risk Prostate Cancer [J]. Front Oncol，2022，12：860848.
[17] Harvey M，Ong WL，Chao M，et al. Comprehensive review of the use of hydrogel spacers prior to radiation therapy for prostate cancer [J]. BJU Int，2023，131（3）：280-287.
[18] Mosquera MJ，Kim S，Bareja R，et al. Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors [J]. Adv Mater，2022，34（2）：e2100096.
[19] Rohr A，Werth K，Shen X，et al. MRI findings of absorbable hydrogel spacer for prostate cancer therapy：a pictorial review [J]. Abdom Radiol（NY），2019，44（1）：247-251.
[20] Fischer-Valuck BW，Chundury A，Gay H，et al. Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer：Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall [J]. Pract Radiat Oncol，2017，7（3）：195-202.
[21] Hwang ME，Mayeda M，Liz M，et al. Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer：toxicity profile and early oncologic outcomes [J]. Radiat Oncol，2019，14（1）：136.
[22] Chao M，Ho H，Chan Y，et al. Prospective analysis of hydrogel spacer for patients with prostate cancer undergoing radiotherapy [J]. BJU Int，2018，122（3）：427-433.
[23] Sch?觟rghofer A，Drerup M，Kunit T，et al. Rectum-spacer related acute toxicity-endoscopy results of 403 prostate cancer patients after implantation of gel or balloon spacers [J]. Radiat Oncol，2019，14（1）：47.
[24] Iocolano M，Blacksburg S，Carpenter T，et al. Prostate Fiducial Marker Placement in Patients on Anticoagulation：Feasibility Prior to Prostate SBRT [J]. Front Oncol，2020，27， 10：203.
[25] 黄定凤，杨洁，宋爱梅.氨磷汀保留灌肠在预防前列腺癌放疗患者肠道毒性中的应用[J].护士进修杂志，2021，36（18）：1685-1688.
[26] 李傲梅，高杰，陆开宇，等.射波刀治疗前列腺癌致放射性直肠炎的护理[J].中华男科学杂志，2017，23（1）：69-72.
[27] 李瑞乾，赵斌，白宇，等.碘125粒子近距离照射联合内分泌疗法治疗前列腺癌[J].实用医学杂志，2017，33（9）：1468-1471.
[28] Morita M，Fukagai T，Hirayama K，et al. Placement of Spa- ceOAR hydrogel spacer for prostate cancer patients treated with iodine-125 low-dose-rate brachytherapy [J]. Int J Urol，2020，27（1）：60-66.
[29] 何尧林，贺秋冬.水凝胶在局限期前列腺癌放疗中的研究进展[J].中华放射肿瘤学杂志，2018，27（8）：789-792.
[30] 杨烨，侯彦杰，薛少军，等.前列腺癌放疗患者植入水凝胶后对直肠保护作用的Meta分析[J].中华放射医学与防护杂志，2021，41（6）：436-443.
[31] 杨烨，侯彦杰，李险峰.水凝胶在前列腺癌和宫颈癌放疗中对直肠的保护[J].中华放射医学与防护杂志，2020， 40（9）：728-732. |
|
|
|
